San Mateo, CA, United States of America

Wang Shen

This inventor holds 45 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Sarcode Bioscience Inc., Abbott Laboratories Corporation, Amgen Inc.. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wang Shen. Retrieved from https://idiyas.com/inventor/wang-shen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 45 

% Patents Active = 82.2


 

Average Co-Inventor Count = 6.1

ph-index = 13

Forward Citations = 446(Granted Patents)


Location History:

  • Skokie, IL (US) (1997 - 1998)
  • Gurnee, IL (US) (2001 - 2010)
  • Jiangsu, CN (2018)
  • Lianyungang, CN (2019)
  • San Mateo, CA (US) (2004 - 2022)

Company Filing History:


Years Active: 1997-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Poly(ADP-Ribose) Inhibitors
Hepatitis C Virus
GPR40 Modulators
Cellular Adhesion Modulators
Thiadiazolidine Derivatives
Quinazoline Compounds
Apoptosis Promoters
Insulin-Related Treatments
Asthma Treatments
Metabolic Disorders
Biaryl Compounds
Protein Isoprenyl Transferases
45 patents (USPTO):Explore Patents

Certainly! Here is the article about inventor Wang Shen:

Title: Innovator Spotlight: Wang Shen - Pioneering Inventor in San Mateo, CA

Introduction:

Wang Shen is a highly esteemed inventor based in San Mateo, CA, with a remarkable track record of 44 patents to his name. His innovative work has significantly impacted the fields of medicine and pharmacology, particularly in the development of novel compounds for the treatment of various diseases and disorders.

Latest Patents:

Wang Shen's latest patents showcase his ingenuity in creating groundbreaking solutions for medical challenges. One such patent is for the invention of alkyne substituted quinazoline compounds, serving as irreversible ErbB kinase inhibitors with implications in the treatment of hyperproliferative disorders like cancer. Additionally, his patent on tricyclic inhibitors of poly(ADP-ribose)polymerase highlights his contribution to developing potent compounds for conditions involving PARP, such as cancer, inflammatory diseases, and ischemic conditions.

Career Highlights:

Throughout his career, Wang Shen has made significant contributions to the biopharmaceutical industry. He has held key roles at renowned companies such as Sarcode Bioscience Inc. and Abbott Laboratories Corporation, where his expertise and innovative mindset have driven advancements in medical research and drug development.

Collaborations:

In his pursuit of excellence, Wang Shen has collaborated with esteemed professionals in the field, including Kenneth Jay Barr and Johan D Oslob. Together, they have worked on pioneering projects that have pushed the boundaries of science and medicine, paving the way for new treatment modalities and therapeutic interventions.

Conclusion:

In conclusion, Wang Shen stands as a testament to the power of innovation and dedication in the realm of inventing. His prolific career and numerous patents underscore his commitment to improving healthcare outcomes and addressing unmet medical needs. Wang Shen's work continues to inspire and shape the future of pharmacology, making him a true trailblazer in the field of medical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…